CHRM1 and prostate cancer: Cholinergic signaling promotes tumor invasion and metastasis in mouse models of prostate cancer, the inhibition of which can be achieved by pharmacologic blockade or genetic disruption of the Type 1 cholinergic muscarinic receptor (CHRM1) [38].